माइटोटेन और उब्रोजेपेंट का इंटरैक्शन

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.

CYP3A4 I nducers Co-administration of UBRELVY with rifampin, a strong CYP3A4 inducer, resulted in a significant reduction in ubrogepant exposure [ s ee Clinical Pharmacology ( 12.3 ) ] .

Dose adjustment is recommended with concomitant use of UBRELVY and moderate or weak CYP3A4 inducers [see Dosage and Administration ( 2.2 )] .

In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St.

Co-administration of UBRELVY with moderate or weak CYP3A4 inducers was not evaluated in a clinical study.